INDIRA ADAPA: Open Payments
NPI 1588776918 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,563 in 41 payments from 10 companies in 2025. Trend: 2023 $1,009 · 2024 $1,090 · 2025 $1,563
Food & beverage: $1,563
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 9 | $354 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $324 |
| Teva Pharmaceuticals USA, Inc. | 4 | $282 |
| Alkermes, Inc. | 9 | $243 |
| Axsome Therapeutics, Inc. | 3 | $219 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Lundbeck LLC | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
| Neurocrine BioSciences, Inc. | 1 | $15 |
Products named: CAPLYTA, COBENFY, Auvelity, UZEDY, LYBALVI, AUSTEDO XR, ARISTADA, REXULTI.
Industry payments across CA — which companies pay providers there.
